Revolutionary Blood Test Enables Early Detection of Coronary Heart Disease

Cardiovascular disease (CVD) remains one of the leading causes of death globally, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. Now, a new test aids in the early detection of coronary heart disease to better enable the management of this condition for preventing a symptomatic event such as a heart attack.

Cardio Diagnostics Holdings Inc. (Chicago, IL, USA) has launched PrecisionCHD, the first integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Using epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers along with a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points, PrecisionCHD detects coronary heart disease with better than 75% sensitivity in both men and women.

Image: PrecisionCHD is the first integrated epigenetic-genetic-based blood test for the early detection of coronary heart disease (Photo courtesy of Cardio Diagnostics)

Importantly, PrecisionCHD is accompanied by a provider-only Actionable Clinical Intelligence platform, which maps a patient’s unique biomarker profile onto modifiable risk factors like diabetes, hypertension, hypercholesterolemia, and smoking, which are considered to be critical drivers of coronary heart disease. The non-invasive, simple test offers healthcare providers a complement to traditional CHD diagnostic solutions and provides an informative, personalized patient report of CHD status.

“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

Related Links:
Cardio Diagnostics Holdings Inc.